AUTHOR=An Wen , Kang Ju-Seop 

TITLE=Effect of Metformin on Myocardial Injury Induced by Hepatic Ischemia-Reperfusion in Rats

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.822743

DOI=10.3389/fphar.2022.822743

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> There is no effective medication for treatment or prevention of hepatic ischemia-reperfusion (HIR) injury caused by liver transplantation and hepatectomy. This study aimed to investigate the therapeutic effects of metformin on HIR injury and related myocardial injury in rats.</p><p><bold>Methods:</bold> Wistar male rats were randomly divided into four groups: sham group, ischemia-reperfusion group, and IR group treated with metformin 150 mg/kg and 100 mg/kg. Wistar male rats were administered metformin 150 mg/kg, 100 mg/kg or saline 30 min pre-operative and underwent 15 min ischemia and 6 h reperfusion (<italic>n</italic> = 4).</p><p><bold>Results:</bold> Metformin significantly alleviates the injury caused by HIR. Administration of metformin resulted in a significant reduction in the serum levels of alanine transaminase and aspartate transaminase and the activity of malondialdehyde, creatine kinase-MB, and lactate dehydrogenase but maintained high catalase and superoxide dismutase activity. Metformin significantly inhibited the IR-induced elevation of tumor necrosis factor-<italic>α</italic> in liver and heart tissue.</p><p><bold>Conclusion:</bold> Metformin can alleviate hepatic and myocardial injury induced by IR by inhibiting oxidative stress.</p>